MedTrace Logo

Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)

NCT04480138 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2022-07-12

No results posted yet for this study

Summary

This is a phase II, multicenter, open-label, randomized, comparator-controlled study to evaluate the efficacy and safety of Pegylated Interferon -α2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).Initial 1 mcg/kg of Pegylated Interferon-α2b will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered with recommended standard care during the trial.

Conditions

  • Covid19

Interventions

DRUG

Pegylated Interferon-α2b

1 mcg/kg on day 1 and day 8 after safety evaluations.

OTHER

Standard of Care

Standard of care as per local authority

Sponsors & Collaborators

Principal Investigators

  • Dr Deven Parmar, MD · Cadila Healthcare Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-11
Primary Completion
2021-06-21
Completion
2021-06-21

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04480138 on ClinicalTrials.gov